Aerpio Therapeutics Financing
Aerpio Therapeutics, Inc., Corporation just submitted form D about $4.60 million debt financing. This is a new filing. Aerpio Therapeutics was able to sell $3.47 million so far. That is 75.42% of the financing offer. The total financing amount was $4.60 million. The financing form was filed on 2016-11-10. The reason for the financing was: unspecified. The fundraising still has about $1.13 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.
Aerpio Therapeutics is based in Ohio. The company’s business is Biotechnology. The SEC form was submitted by Joseph H Gardner President and CEO. The company was incorporated in 2011. The filler’s address is: 9987 Carver Road, Suite 420, Cincinnati, Oh, Ohio, 45242. Joseph H. Gardner is the related person in the form and it has address: C/O Aerpio Therapeutics, Inc., 9987 Carver Road, Suite 420, Cincinnati, Oh, Ohio, 45242. Link to Aerpio Therapeutics Filing: 000153847216000002.
Analysis of Aerpio Therapeutics Offering
On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Aerpio Therapeutics sold 75.42% of the offering. The fundraising is still open. Could this mean that the trust in Aerpio Therapeutics is high? The average investment floor size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 12.63% bigger than the average for companies in the Biotechnology sector. The minimum investment for this financing is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Aerpio Therapeutics Also
The Form D signed by Joseph H Gardner might help Aerpio Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.